Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations
{{output}}
Although recent extensive efforts led to the landmark discovery of clinically effective KRASG12C inhibitors (KRASG12C-i), targeting RAS genetic alterations beyond the G12C mutant remains challenging. Here we report on LUNA18 (paluratide), an orally available c... ...
